Blog

TRAVELLESS
Homeworking: The positives and tips from our experience

The current social distancing measures to combat the spread of COVID-19 are essential and many companies have closed their offices and facilities, asking their employees to work from home.  Whilst most will have worked from home periodically, longer periods can become difficult for some, as we miss the social norms and interactions of the workplace.

The place of real-world evidence in the market access strategy

The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in Real-world challenges and real-world data, understanding the payer’s perspective, in Payers use real-world data cautiously, and seeing the views of both advocates and opponents of […]

How do companies prepare for reimbursement?

Market Access functions have one major objective: to achieve rapid reimbursement (coverage, funding) at an acceptable price for their products. Over the last 10 years, we have witnessed how companies – from very small ones to large top ten corporations – try to handle this. We are certain that most companies believe they do it […]

The growing clinical importance of patient-reported outcomes (PROs)

Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the evaluation of health and healthcare interventions. In the Valid Insight webinar ‘Patient-reported outcomes in clinical trials and studies,’ we discussed the clinical implications of PROs […]

How to weather pricing competition

Over the years, the threat of pricing competition has increasingly become a concern. In a Valid Insight webinar on ‘Sustainable price competition –contradiction in terms?’, we discussed how price competition occurs, its potential impacts, as well as some tips for how companies can alleviate price competition.1 How pricing competition occurs If prices escalate, payers can […]

Valid Insight Paperless
Putting people and the planet first in 2020

At Valid Insight, we attend and participate in many conferences each year. We think it’s vital in helping us continue to be inspired and innovate, to share our insight and expertise, and in turn help others be inspired and continue to transform healthcare. Ultimately, we hope this contributes towards the common goal: improving health outcomes. […]

Market Access and Pricing Experts
The balancing act that’s keeping pharma and biotech market access on its toes

The launch of gene therapies introduced new benchmarks for pricing of pharmaceutical interventions. CAR-T cell therapy costs close to $500,000 per patient in the US, and €300,000 in Europe. Zolgensma®, gene therapy for the treatment of spinal muscular atrophy, is (at the time of writing) the most expensive drug in the world at $2.1m. Whilst such companies claim these […]

Real-world data
Is real-world evidence the holy grail: Finding the balance

We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer’s perspective, in Payers use real-world data cautiously. In our third instalment, we’re looking at how to find the right balance in using RWE. With the rapidly growing availability of […]

Real World Data Market Access
Payers use real-world data cautiously

Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously. While companies and regulators are becoming increasingly enthusiastic about RWD and RWE, payers remain cautious. They’re using concerns […]

real-world data
Real-world challenges and real-world data

This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access. RWD and RWE are high on the list of priorities for the top 20 pharmaceutical companies. According to Deloitte, 90% of them are investing in RWE capabilities across the entire product lifecycle. […]